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Methods

Introduction
• In the in-patient setting, physicians routinely administer
anticoagulation (AC) therapy to treat venous
thromboembolism (VTE). However, AC therapy is often
held in neurosurgical patients undergoing craniotomies
due to the risk of intracranial hemorrhage (ICH)
associated with this operation.
• A craniotomy is a procedure involving the removal of the
skull.
• Examples:
• Meningioma resection
• Aneurysm clipping
• Cavernous malformation resection

• In addition to ICH, these patients are at an increased risk
for post-operative VTE. It is estimated that 50% of patients
experience VTE post-craniotomy.
• Both ICH and VTE are serious complications that can
lead to significant morbidity or death.
• Currently, there is no standard protocol for VTE therapy
following craniotomy. This continues to challenge
neurosurgeons when determining the most appropriate
management of anticoagulation therapy after craniotomy
to simultaneously mitigate the risks of ICH and VTE.
Aim: In this study, we reviewed the time frame of AC
therapy administration as well as the incidence of ICH and
other complications following AC therapy in patients after
craniotomy.

We performed a retrospective chart review of all craniotomy patients
from August 2017 and July 2021. Patients were selected if they received
anticoagulation therapy following a VTE. Additionally, demographics and
clinical data were collected including age, gender, reason for operation,
day and time of AC administration, and type of AC received.

Results
• Forty patients met the inclusion criteria. 50% male and 50% female.
Average age 49.35.
• The most common indication for starting anticoagulation was a
deep venous thromboembolism and pulmonary embolism.
• The initial type of anticoagulation used in 27 patients was
unfractionated heparin (67.5%), followed by a novel oral
anticoagulant 8 (20%), low molecular weight heparin 4 (10%) and
warfarin at (2.5%).
• The range of initiation of anticoagulation therapy after surgery was
from post-op day 2 to post-op day 107. The average time of AC
therapy administration was post-op day 10.
• Five of the forty patients (12.5%) experienced complications
following anticoagulation therapy with three of the five experiencing
an intracranial hemorrhage. None of the patients who experienced
complications required revisional surgery.
• Three of the five patients developed a new intracranial
hemorrhage.
• One of the five patients developed Heparin-Induced
Thrombocytopenia (HIT) and responded to Argatroban therapy.
• One of the five patients developed a tracheostomy hemorrhage.
• Once the patients with complications were stable, their
anticoagulation therapy was restarted.

Discussion
• VTE is the most common preventable post-operative
complication leading to mortality.
• The need for a standard protocol for the therapeutic
administration of anticoagulation has become more
imperative
• Routinely, it has become common for neurosurgical patients
to be given LMWH or UFH as VTE therapy.
• Our study resulted with favorable insight to the safe
therapeutic administration of anticoagulation following
craniotomy; however, the best time frame to initiate the
anticoagulation remains unclear.

Limitations
• As a retrospective chart review, our study lacked a
comparison group which would need to be included in future
studies to further confirm the validity of our study.
• Our sample size was small due to the low incidence of
therapeutic anticoagulation use following the total number of
craniotomies within our institution.
• In the future, it may be beneficial to collaborate with other
institutions to execute a prospective study to increase the
sample size, include comparison groups, and control for
bias and confounding variables.
• Additionally, we found that there was no standard to the
choice of AC therapy. It was given based on the surgeon’s
preference.
• A prospective study of specific AC therapy given after
craniotomy would aid in the development for a more
standard protocol of AC therapy administration after
neurosurgery.
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Conclusions
We conclude that our results display evidence for a
benefit to anticoagulation therapy after craniotomy.
Moreover, our results appear to exhibit the potential for
safe administration of AC therapy earlier after craniotomy
than previously observed.
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